Develop AI-based risk stratification and care-pathway SaaS tools to manage Social Security Disability Insurance and social determinants of health for over 2.2 million Americans. Leading predictive analytics tool for providers, health plans, benefit, health, life and stop-loss insurers and self insured employers to manage populations and individuals with post-pandemic conditions.

Support public/private alliances to finance and coordinate the development and supply of new vaccines and other countermeasures to prevent and contain infectious disease epidemics. Creating new sustainable business models, de-risked financing, vaccine (DVT) innovations, healthy markets, technology workforce and training programs, supply chain; WHO,WTO and IP regulations and public health governance structures to improve access to new vaccine technologies.

I am co-leading the Regional Vaccine Manufacturing Collaborative (RVMC) of the WEF chaired by CEPI and the US National Academy of Medicine. The RVCM aims to increase vaccine access for low- and middle-income countries through successful and sustainable establishment of a versatile global vaccine manufacturing network capable of producing vaccines during pandemic and non-pandemic times.

Member of the Board of Directors for a privately-held, research-stage, drug delivery company focused on delivering cancer chemotherapy and other established drugs with a limited therapeutic window to tumors and affected organs. Over $5M raised. Two drug candidates entering human clinical trials in 2024. Member of Scientific Advisory Board and Compensation sub-committees.

Warmilu manufactures non-electric warming blankets to prevent hypothermia in infants. Every year our warming solutions save the lives of over 15,000 infants in almost 100 countries where electricity is not available. We are the preferred solution of Doctors Without Borders and the International Rotary Club.

Life Sciences and Healthcare Practice Manager. Specialize in digital and biomedical tech transformation, focusing on the clinical development, market launch and commercial optimization of next-gen biopharmaceutical and med-tech products. Led the global redesign of the Essential Medicine supply chains for the U.S/FDA, EU/EMA, the Japanese Ministry of Health to ensure post-COVID access to critical DTV and PPE supplies. AI/ML, predictive and big-data-based patient journey management. Authored firm thought capital: global regulatory management best practice guides and customer-oriented process optimization methodologies. Recruited and hired over 60 strategy consultants to the firm. Transitioned to part-time support role, August, 2023

C-suite strategy and operations consulting to healthcare providers, insurers and suppliers.Operation Warp Speed - Senior Advisor to 2 administrations. Led regulatory strategy for vaccine EUA acceleration for nine DVT products. Supported vaccine roll-out and logistics optimization in US, EU and 11 other nations for first 2B doses shipped. • Predictive Analytics and AI Population HIT Company – Funding by BCBS Association and Intel to develop AI-based analytical models that predict individual and population clinical conditions. Savings of $700PMPY achieved through risk adjustment, risk sharing, underwriting and care management across the Blues Networks, • Major Life Sciences Company – Led product roll-out and expansion into new channel. Negotiated channel partnerships, developed reimbursement strategy and developed internal sales team. Achieved $200M additional sales in year one. • COO of clinical trial network and registry company leading real-life trials, and outcomes research. Led PD1 inhibitor pivotal trial network. Global operations in 16 countries. Managed P&L, personnel deployment, product lifecycle, client sales and delivery. Raised venture funding.• Leading Academic Medical Center - Office of Strategic Program Management: Opened new PMO reporting to Executive Council to re-engineer operations across academic health system. Launched PMO lifecycle methodology. Staffed and trained program management leaders and project teams. Launched Value Margin Improvement Program in 4 waves to improve margins from -1.7% to +3.2% in one year.• C-Suite, Leading Global Clinical Research Organization: Led launch of new $200M Solutions Division for leading Contract Research Organization. Drove solutions and contracted new work. Transitioned delivery teams and marketing/sales support to new operations. Supported two pharmaco jv’s.• BD/Licensing - Gene-Edited Lab Animal Testing Company: Supported over 40 clinical development partnerships.• COVID - see fredbrown.com

Member of the Board of Directors and R&D Partnerships and Audit Subcommittees of leading hepatic, metabolic and organ modelling biopharmaceutical company from initial raise through Series C capitalization - over $40M raised. Helped commercialize Reveal-Tx solution offering to the CRO and pharma industry, hire executive and scientific teams, initiate and manage mulit-million dollar, multi-year drug development partnerships with top 10 biophamaceutical manufacturers and develop internal drug portfolio. HemoShear recognized by White House as largest NIH grant recipient in 2012, 2013 and 2014.

Newly created position reporting to System CEO, responsible for all strategy planning, innovation and business development for Michigan Market. Executive Change Agent across the system of care. Board Member of 3 hospitals and lead System-wide Strategy, IP and IT Boards. • Led regional annual strategy and budgeting teams and process. • Oversaw internal and external joint ventures and partnerships. Led private equity partnering and fund raising to support acquisition of new care technologies, products and services across the network.• Sponsored internal and external innovation programs in medicine, informatics, regulatory compliance, and new business models.• Supported Pioneer ACO program, grew physician networks, launched national home care operations and continuum of care programs, expanded insurance risk-sharing and awarded meaningful-use monies across the network.• Established a comprehensive change program of over 70 projects and JV’s that grew the system market value 30% in five years, and supported access to external PE funding.

Developed global client base across new healthcare supply, provider and insurance companies to become the 7th largest M&A advisory in the state of Michigan. Led several new business launches for healthcare clients, as well as merger / post-merger integration and executive coaching.• Negotiated and implemented a $3.5B merger of a biotech and major pharmaceutical company.• Evaluated new product extension opportunities in BRIC countries for a major healthcare company.• Assessed the financial and strategic impact of PPACA regulations on healthcare suppliers, providers and payors.

Led Diplomat Specialty Pharmacy, world’s largest independent specialty pharmacy, in raising $200M of non-dilutive funding. Developed and sold outsourcing services and consulting to research hospitals, CROs, biotech and pharmaceuticals in clinical data management / analysis, patient assistance funding (PAP) co-pay, CER/REMS, and triple aims improvement programs. Led managed care and reimbursement contract services to providers and insurers.• Raised $200M of external capital to execute growth strategy and grew sales to $670M, improving EBITDA over 25%.• Diplomat awarded Inc. Magazine “Fastest Growing Healthcare Company" -- 2009.

1997 - 2001. Led launch of CSC Life Sciences and Healthcare in Europe. Designed strategy and built business from scratch, growing sales to over $100M and increasing team from 3 to over 40 consulting professionals. Developed industry-wide, global reputation for excellence in Healthcare PLM, clinical development project management, regulatory compliance, and transformational change management.SVP and Global Head of Chemicals, 2008 - 2009Returned from Europe to the US and was recruited back to CSC with mission of creating consulting and outsourcing service portfolio for major chemical producers worldwide. Developed REACh and margin improvement programs generating over $10M of annual revenues.

Championed new portfolio and partnering strategy to increase overall corporate profitability by 7%. Led Global 200-person staff with annual budget of $100M with strategic mission of profit optimization of the Pharmaceutical Division portfolio. Also led teams supporting all Roche external partnerships and project management, which involved over 70 business partnerships (including Genentech, Chugai, and Ventana) and over 10,000 professionals globally. Ran over 50 concurrent business change programs. Implemented new near- and offshore outsourcing organizations that reduced costs 30% while improving service metrics by 80%.

Responsible for Watson/Life Sciences business in EMEA. Hired and led over 1000 professionals, becoming largest healthcare services organization in Europe. Grew sales to $1.2B in 3 years across 62 countries in Europe, Middle East and Africa (EMEA). Maintained profit contribution of over 35% and was #1 growth business division in all of IBM. Managed client relationships and delivery of over 180 solution design and implementation programs at biopharmaceutical and healthcare companies to improve innovation, development and product management strategies and operations. Launched near and off-shore development companies in Eastern Europe and Asia. Led IBM’s entry into Service-Oriented-Architecture (SOA), launching 5 new solutions and training over 700 professionals to double growth rates.

Co-founded the Pharmaceutical and Medical Products Practice (PMP). Created strategy and business plan, developed thought capital and methodologies, built team, and sold and delivered projects. Grew NA Practice to 250 professionals and $385M in 5 years; and then Continental Europe to 125 professionals and $250M.

Co-founded pharmaceutical company (NASDAQ: ALKS) that has become the world's largest in depo injection, drug formulation and delivery company with 20 marketed products and $5B in assets.